| Original language | English (US) |
|---|---|
| Pages (from-to) | 277-280 |
| Number of pages | 4 |
| Journal | Annals of the American Thoracic Society |
| Volume | 16 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2019 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Discordance between imaging modalities in the evaluation of chronic thromboembolic pulmonary hypertension : A combined experience from two academic medical centers. / Furfaro, David; Azadi, Javad; Housten, Traci; Kolb, Todd M.; Damico, Rachel L.; Hassoun, Paul M.; Chin, Kelly; Mathai, Stephen C.
In: Annals of the American Thoracic Society, Vol. 16, No. 2, 02.2019, p. 277-280.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Discordance between imaging modalities in the evaluation of chronic thromboembolic pulmonary hypertension
T2 - A combined experience from two academic medical centers
AU - Furfaro, David
AU - Azadi, Javad
AU - Housten, Traci
AU - Kolb, Todd M.
AU - Damico, Rachel L.
AU - Hassoun, Paul M.
AU - Chin, Kelly
AU - Mathai, Stephen C.
N1 - Funding Information: Supported by a grant from the Vitality Institute to the University of Pennsylvania Center for Health Incentives and Behavioral Economics, and National Institutes of Health/National Heart, Lung, and Blood Institute grant K99 HL141678 (M.O.H.). Funding Information: Supported by National Heart, Lung, and Blood Institute grant HL125175 and the Scleroderma Foundation (S.C.M.). K.C. has received research support from with Actelion, Bayer, Geno Pharmaceuticals, the National Institutes of Health (NIH), SoniVie, and United Therapeutics and has received reimbursement for work on advisory boards for Actelion and United Therapeutics. S.C.M. has received research support from the NIH and the Scleroderma Foundation, has received consulting fees from Actelion and United Therapeutics, and serves on the Pulmonary Hypertension Association Scientific Leadership Council and the Patient-Centered Outcomes Research Institute Rare Disease Advisory Panel.
PY - 2019/2
Y1 - 2019/2
UR - http://www.scopus.com/inward/record.url?scp=85060910504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060910504&partnerID=8YFLogxK
U2 - 10.1513/AnnalsATS.201809-588RL
DO - 10.1513/AnnalsATS.201809-588RL
M3 - Letter
C2 - 30359536
AN - SCOPUS:85060910504
VL - 16
SP - 277
EP - 280
JO - Annals of the American Thoracic Society
JF - Annals of the American Thoracic Society
SN - 2325-6621
IS - 2
ER -